Ex-Attorney General Bill Barr discusses President Donald Trump’s shocked reaction to Jeffrey Epstein’s apparent suicide when he called to tell him the news in
Wall Street analysts see NextEra (NEE) as a buy: Should you invest?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed
The top performing homebuilder stocks YTD as sector maneuvers challenging outlook
The following list ranks homebuilding companies (XHB) in descending order based on their year-to-date performance.
Bitcoin will climb to $143,000, according to this Wall Street forecast
Bitcoin will rally to $143,000 next year as investors continue to increase digital-asset adoption through exchange-traded funds, according to a new Wall Street forecast.
Wall Street opens higher on tech rebound, Nike slumps
Wall Street’s main indexes opened higher on Friday, as technology stocks extended their rebound from an early-week selloff, while Nike tumbled after weak China
Latin America shifts right in 2025 and aligns with Trump
A new regional political map for Latin America is marked by the erosion of progressive projects and the advance of right-wing alternatives.
Trump hopes North Carolina speech will bolster his standing on US economy
U.S. President Donald Trump will travel to North Carolina on Friday, seeking to convince Americans that his handling of the economy is sound ahead
Trump official previews the release of the Epstein files
For years, conspiracy theorists and right-wing commentators have called for the public release of the files from Epstein’s sex-trafficking case, along with any information
Invest $500 Per Month to Create $240-$300 in Passive Income in 2026
Invest $500/month → $6,000 by end of 2026, which at a 4–5% yield would generate about $240–$300 in annual passive income. Keep investing and
LIVE: OKYO Pharma Ltd Rings the Opening Bell
About This EventOKYO Pharma Ltd (Nasdaq: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition